Risperdal events, FDA actions and Lawsuits

Young boys or mens who have developed breasts as result of Risperdal  drug use can suffer from severe mental or psychological trauma. As a result, many doctors have recommended that adolescent males or young boys who suffer from gynecomastia have to under go through surgery. Mild cases can be resolved with liposuction surgery, where as more severe cases will require a mastectomy surgery.

Patients who have taken the prescribed generic called Risperdal medication and have suffered from serious side-effects do have legal rights and they may be able to file a lawsuit against the pharmaceutical manufacturer for their injuries. Often times, lawsuits filed against manufacturers of this drug can result in significant settlements.

Currently, generic Risperdal lawsuits are being filed on behalf of patients suffering from:


Development of breast tissue in males (breast development)

Heart problems



Tardive dyskinesia

Neuroleptic Malignant Syndrome (NMS)

Risperdal medication has one of the longest histories of difficulties and disputes of any medication on the market and at its peak, Risperdal drug was the most common antipsychotic used in the US. 

Marketing abnormalities including inappropriate marketing for unapproved uses in children and adults and for other indications such as ADHD, chemical restraint and schizoaffective disorder has been reported in 1994, shortly after the medication was approved to treat Schizophrenia. 

Harms caused by Risperdal use was noted as early 2001 and litigation is still ongoing.  This drug maker company has paid well over $5 billion in fines and settlements to date. To read FAQs about Risperdal Lawsuits, you can also navigate here.

If you or a loved one has used Risperdal drug and suffered from gynecomastia condition, you may have legal recourse to collect compensation for surgical expenses, hospital bills, mental anguish and other damages.

Attorneys for the victims have claimed that Johnson & Johnson and its subsidiary, Janssen used illegal marketing to promote Risperdal drug for unapproved uses even after they were aware of the threats of  gynecomastia, movement disorders and even the risk of death and that they minimized and did not adequately warn of those risks.